PDCD1 and neoplasm: Anti-PD-1 treatment increases the transfer of Tcf1+Tim3- progenitor exhausted (dysfunctional) CD8+ T cells into the B16 melanoma tumour, but not of their Tcf1-Tim3+ terminally exhausted counter parts [124].